Showing posts with label Biotechnology. Show all posts
Showing posts with label Biotechnology. Show all posts

Thursday, July 24, 2014

Where to Invest: With Macroinvestors or Macroeconomists?

Frederick J. Sheehan is the author of Panderer to Power: The Untold Story of How Alan Greenspan Enriched Wall Street and Left a Legacy of Recession (McGraw-Hill, 2009), which was translated and republished in Chinese (2014). He is researching a book about Ben Bernanke. He writes a blog at www.AuContrarian.com.

            Stanley Druckenmiller, the justly renowned investor, spoke at the Delivering Alpha conference on Wednesday, July 16, 2014. Quoting Druckenmiller: "As a macro investor, my job for 30 years was to anticipate changes in the economic trends that were not expected by others - and therefore not yet reflected in securities prices. I certainly made my share of mistakes over the years, but I was fortunate enough to make outsized gains a number of times when we had different views from various central banks."

            Druckenmiller went on to discuss, among much else that deserves reading, how the Fed's emergency 1.0% fed funds rate in 2003-2004 defied conditions observed by him and his colleagues at Duquesne Capital. Where was the emergency? In short: "[W]e were confident the Fed was making a mistake, but we were much less confident in how it would manifest itself. However, our assessment by mid-2005 that the Fed was fueling an unsustainable housing Bubble, with dire repercussions for the greater economy, allowed our investors to profit handsomely as the financial crisis unfolded."

            Today, Federal Reserve Chairman Janet Yellen sounds more preposterous every time she opens her mouth. Last week, maybe it was two weeks ago, she offered America a sector analysis, proposing that small-cap and biotech stocks look overpriced. A few days later, ECB President Mario Draghi offered his opinion of no widespread asset bubbles, although some markets looked "frothy."

            It has been less than a decade since Fed chairman Greenspan declared there was no housing bubble, though he saw signs of "froth." His weasel act warranted derision, which is just what it received, such as in the Economist's headline: "Frenzied Froth" (May 28, 2005). Draghi is acclaimed for his well-tailored suits but they stink of old mothballs. He's a botoxed Greenspan.

            The two of them - that would be Yellen and Draghi - have decided to let markets take their course, now that the Fed and ECB have used every possible mechanism to create mispricings in all markets. They will administer regulatory measures, if necessary.

            The only such declaration of any use would be to administer the two of them, along with their supercilious staffs, out of existence. Instead, the average person who reads newspapers that include even a moderate degree of financial reporting knows multiple crashes are building.

The all-star break results are in. That is, the announcements of how first-half 2014 security issues compare to earlier years. We can congratulate ourselves. Never before has the world shown such indulgence, intemperateness, and unconscionable underwriting as in 2014.

"Megadeals... helped push the number of debt sales by highly rated companies in the U.S. to record levels in the first half of the year. These companies sold about $642 billion of debt." That "outstrips the previous record set in 2009, when $612 billion of bonds was sold..." (Wall Street Journal, July 1, 2014) Aside from the probable default rate (where are you now, TXU?), megadeals are no friend to the workers.


"As investors scour the landscape for income, the first half of the year saw record amounts of new corporate bond issuance as well as record issuance of collateralized loan obligations. CLOs are securitized vehicles that invest in bank loans made to junk-rated companies, first pooling the loans and then dividing them into tranches to be sold to investors at varying levels of income and risk.... The $58 billion of CLO issuance in the first half of this year puts 2014 on pace to top $100 billion and break the previous single-year issuance record...set in 2007." (Wall Street Journal, July 2, 2014) Pension plans and insurance companies are large buyers of such attempts to increase yield; an attempt to reinstitute the yield confiscated by the same central banks that have now declared their forbearance in monitoring default-prone issues.

Doug Noland, manager of the Prudent Bear Fund, in his Credit Bubble Bulletin, written on July 11, 2014, analyzed the seven-year itch, under the appropriate title: "2014 vs. 2007":

"From my perspective, 2014 and 2007 share troubling similarities. Both periods feature overheated securities markets, replete with the rapid issuance of securities at inflated valuations. Both are characterized by investor exuberance in the face of deteriorating fundamentals - and in both cases central bank policymaking was fundamental to heavily distorted market risk perceptions. It's no coincidence that today's overheated backdrop - record securities issuance and meager risk premiums/record high prices - readily garner statistical comparison to 2007.

"This year's booming M&A market has posted the strongest activity since 2007. Second quarter global M&A volume of $1.06 trillion was up 72% from the year ago period. Here at home, M&A more than doubled year-on-year to $473 billion, pushing record first-half volume to $749 billion. The proliferation of deals was fueled by the loosest credit conditions in years. First-half global corporate bond issuance hit an all-time high $2.29 trillion. A record $286 billion of junk bonds were issued globally, as average junk yields traded to the lowest level ever. At $642 billion, first-half U.S. investment-grade company bond sales easily posted an all-time high. The first six months of 2014 also saw record issuance of collateralized loan obligations (CLOs). A record number of global IPOs were sold in the first half, with $90.6 billion of offerings 54% above comparable 2013. Led by technology and biotechnology issues, U.S. IPO sales enjoyed the strongest first-half since the height of the technology bubble back in 2000. According to Dealogic, year-to-date total global sales of corporate stock and equity-linked securities reached an unmatched $510 billion, outpacing 2007's record pace."

It is certain such frivolities are "not yet reflected in securities prices."
 
 

Wednesday, April 16, 2014

Helping the Fellow Out

Frederick J. Sheehan is the author of Panderer to Power: The Untold Story of How Alan Greenspan Enriched Wall Street and Left a Legacy of Recession  (McGraw-Hill, 2009) and "The Coming Collapse of the Municipal Bond Market" (Aucontrarian.com, 2009)

After biotech stocks hiccupped on Thursday, April 11, 2014, ISI analyst Mark Schenebaum told the world: "Horrible day in biotech. I'm frankly at a loss for an explanation. And it's my job to know why. [The reason he gets paid the big bucks - FJS.] Schenebaum "has been following the sector since 2000," but maybe spent too much time golfing.

  NASDAQ 2000: To the Brink and Back

Closing Price
Point Change
Percent Change
March 10
5048
+182
+1.7%
March 13
4907
-141
-2.8%
March 14
4706
-201
-4.1%
March 15
4582
-124
-2.6%
March 16
4717
+135
+2.9%
March 17
4798
+81
+1.7%
March 20
4610
-188
-3.9%
March 21
4711
+101
+2.3%
March 22
4864
+153
+3.2%
March 23
4940
+76
+1.6%
March 24
4963
+23
+0.5%
March 27
4958
-5
-0.1%
March 28
4833
-125
-2.5%
March 29
4644
-189
-3.9%
March 30
4457
-186
-4.0%
March 31
4572
+115
+2.5%
April 3
4223
-349
-7.6%
April 4
4148
-75
-1.8%
April 5
4169
-21
+0.5%
April 6
4267
+98
+2.3%
April 7
4446
+179
+4.1%
April 10
4188
-258
-5.8%
April 11
4055
-133
-3.2%
April 12
3769
-286
-7.1%
April 13
3676
-93
-2.4%
April 14
3321
-355
-9.6%
April 17
3539
+218
+6.6%
April 18
3793
+254
+7.4%

Source: John Hancock Quarterly Market Review and Outlook, July 3, 2000, Frederick J. Sheehan, Andrea Whalen

Schenebaum is not alone. "Biotech Rout Perplexes Analysts," ran the Wall Street Journal headline. On April 10, the NASDAQ Biotechnology Index (NBI) fell 5.6%. The day before, it rose 4.1%. This is familiar ground. The NASDAQ (composite) chart from early 2000 - "The NASDAQ - To the Brink and Back" - shows many days a believer found encouragement to plunge on, but this was not the wise course.  

            Dr. Joseph Lawler, Senior Managing Partner at Merus Capital Management, told a Grant's Interest Rate Observer conference audience (April 8, 2014) the NBI trades at 42 times reported earnings. To arrive at that multiple, several leaky faucets need to be plugged. Removing the contrivances, including losses, the NBI is poised at 2,200 times current earnings. The NBI market capitalization is greater than the domestic automobile and aerospace industries added together.

Speculators want to make money. They buy what is going up. If it keeps going up, they buy more of it. They may "climb the wall of worry," as the saying goes, but get used to that. More savers decide they need to gamble so that they can eat, so jump in. The increasing participation is common to market excesses. Then more savers stare at the cat food in the cupboard and climb aboard.

            Leverage contributes to the rising tide. Glenn Holderreed at Quacera L.L.C. in Sacramento, California reported on April 6, 2014, New York Stock Exchange margin debt is close to $500 billion. This is well above the highs in 2000 and 2007, after adjusting for price inflation.

            It is often said how much faster a bull market dives than the time it took to rise. The reason involves panic, or a synonym of that. There is also a mechanical reason. It resides somewhere in our minds but the mechanism is worth repeating after a period of relative calm. From the April 6, 2014, Quacera Chronicle: "When setting up a margin account with a stock brokerage, the typical maximum for margin debt is 50% of the value of the account. In order to prevent a margin call (a request to raise collateral* in the account), the margin debt must remain below a specified percentage level of the total account balance, known as the minimum margin requirement. If stock prices fall the brokerage insists the margin debt be reduced, either by putting up additional money or selling stocks.... Unfortunately [for the margined punter in bio or Tesla - FJS] brokerage firms and banks want margin calls (demand for debt payments) paid on the same day." A brother-in-law broker might "want" and wait, for the rest, without payment, their stocks are sold.

*Collateral: There is probably no part of what remains of the so-called financial system that is more an illusion than collateral. The central banks have taken possession of government and agency securities that are ranked at or near the top in the hierarchy.

At the most basic level of collateral, we can wonder until Doomsday why the United States government has refused to return the German government's gold stored in New York. In January 2013, Germany demanded the U.S return 300 tons of the 1,500 tons it keeps stored at the New York Federal Reserve. At last count, the U.S. has returned three (3) tons. As a working assumption, the U.S. government cannot return it. It therefore does what it can to drive the price of gold down. A few minutes after Ukrainians and Russians (or their proxies) started shooting this morning, April 15, 2014, gold opened for trading in New York. Almost immediately, "over half a billion dollars of notional... gold futures contracts" were dumped. "This smashed gold futures down over $12 instantaneously, breaking below the 200 [day moving average] and triggered the futures exchange to halt trading in the precious metals for 10 seconds." (Zero Hedge)

It does not pay (over time, one must add) to mess with mother nature. Nothing is worse (in the long run) than attempting to destroy the very roots of money.  For at least 5,000 years, money has been an immovable object planted in bedrock to protect the people from the folly and vanity of human weakness. To cripple gold's function destabilizes the financial ecosystem at every level. Witchcraft hexes on currencies, through money markets, bonds, common stocks, and uncommon stocks including the never-never, nothing-nothing, gossip and Peeping Tom shares as well as the medicine man miracle cures begs for annihilation.